CFRA Reiterates Buy Opinion On Shares Of Morgan Stanley

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

MS stands to significantly benefit from the early stage recovery in investment banking and asset management. We lift our target $11 to $108 on a forward P/E of 15.2x, above the 13.6x three-year historic average. We raise our ’24 EPS to $7.10 ($6.60) and ’25’s to $7.75 ($7.20). Our investment thesis is underwriting and advisory (M&A) fees could benefit with CEOs renewing capital formation, and ALT firms later this year needing to monetize from $1T+ investment funds to satisfy limited partners. Our revenue forecast is $59.8B in ’24 and $63.0B in ’25. MS posted Q1 EPS of $2.02, a $0.37 earnings beat. In Institutional Securities, MS realized +113% Y/Y growth in equity underwriting and debt underwriting was +37%. While M&A was -28%, we are confident that will strongly reverse in the coming quarters. The Wealth Management unit realized 5% Y/Y revenue growth and Investment Management was +7%. Equity trading was +4% and FICC was -4%. America’s revenue was +7% Y/Y (76% of total), EMEA +5% (12%), and Asia -12% (12%).

Scroll to Top